peptides

News

HHS doubles down on controversial peptides plan

HHS unveils an enforcement holiday to manufacture of unapproved peptides - before the FDA decides if they should be allowed in compounded medicines.

News

FDA issues warning letters to five unapproved GLP-1 websites

In a handful of strongly-worded warning letters, the FDA is cracking down on sales of unapproved peptides - even if they're labelled for research.

News

Re-rostered FDA committee backs peptide compounding

Against the advice of FDA staff scientists, an advisory committee has narrowly voted in support of looser restrictions on compounded peptides.

R&D

Beyond GLP-1: Preclinical hurdles and solutions for next-gen...

The development experience with GLP-1 analogues offers critical insights for navigating ADME challenges in contemporary peptide programmes.

Market Access

JP Morgan Week 2025 – Jeff Fischer

R&D

Partner Content

2nd Peptide-Based Therapeutics Summit

With Merck’s oral PCSK9 inhibitor demonstrating strong phase 3 trial results, J&J’s IL23R antagonist peptide continuing its phase 3 journey, and Chugai advancing peptides into the intracellular

HHS doubles down on controversial peptides plan

FDA issues warning letters to five unapproved GLP-1 websites

Re-rostered FDA committee backs peptide compounding

Beyond GLP-1: Preclinical hurdles and solutions for next-gen...

JP Morgan Week 2025 – Jeff Fischer

2nd Peptide-Based Therapeutics Summit

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

peptides

Editor's Picks